Taysha Gene Therapies (TSHA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is TSHA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Taysha Gene Therapies, Inc. ( TSHA ) Q3 2026 Earnings Call November 12, 2026 8:30 AM EST Company Participants Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Kamran …

Taysha Gene Therapies NASDAQ: TSHA expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half o…

REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027…

DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $3.55 and last traded at $3.58, with a volume of 6,115,201 …

Taysha Gene Therapies (NASDAQ: TSHA - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based …

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies …

Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivo…

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies…

Bank of America Corp DE raised its stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) by 45.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund own…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

